Protalix Biotherapeutics Inc
PLX
View Detailed Chart
2.066USD
-0.044-2.09%
Market hours （ET）Quotes delayed by 15 min
18.76MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.09%
5 Days
-3.46%
1 Month
-28.26%
6 Months
-4.35%
Year to Date
+14.78%
1 Year
-19.92%
View Detailed Chart
TradingKey Stock Score of Protalix Biotherapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Protalix Biotherapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 86 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Protalix Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Protalix Biotherapeutics Inc Highlights
StrengthsRisks
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 52.74M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -25.45, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 14.38M shares, decreasing 14.17% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 13.74K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.06.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
11.000
Target Price
+421.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Protalix Biotherapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Protalix Biotherapeutics Inc Info
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Ticker SymbolPLX
CompanyProtalix Biotherapeutics Inc
CEOBashan (Dror)
Websitehttps://protalix.com/
Related Instruments
-0.67%
-0.92%
+0.66%
+5.97%
-1.17%
+0.67%
+1.39%
-0.80%
-0.09%
+1.90%
-2.83%
+0.47%
+0.85%
+0.46%
-3.06%
0.00%
+0.21%
-0.80%
+2.39%
+1.16%Popular Symbols
247.180
-1.620 (-0.65%)
166.810
-0.710 (-0.42%)
67247.040
+662.990 (+1.00%)
254.790
-18.560 (-6.79%)
2061.150
+61.150 (+3.06%)
360.367
-1.463 (-0.40%)
4531.960
+39.440 (+0.88%)
102.552
+1.943 (+1.93%)
1.146
-0.004 (-0.38%)
159.465
-0.787 (-0.49%)
